Tech Company Financing Transactions
OncoSynergy Funding Round
OncoSynergy, based in San Francisco, secured $20 million from Connecticut Innovations, Korea Information & Communication Co. and NLabs.
Transaction Overview
Company Name
Announced On
5/5/2018
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$20,006,575
Round
Series A
Investors
Proceeds Purpose
The venture financing will be used to accelerate their lead program, OS2966, to the clinic for the treatment of glioblastoma, the most common and deadliest primary brain tumor in adults.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for cancer patients with gravely underserved needs, particularly glioblastoma, the most common and malignant primary brain cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shawn Carbonell
Chief Medical Officer
Anne-Marie Carbonell
Founder
Catherine Park
Browse more venture capital transactions:
Prev: 5/5/2018: StratiFi Technologies venture capital transaction
Next: 5/5/2018: SnapMD venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs